Russia will soon begin testing an mRNA vaccine on cancer patients.

The first group to receive the mRNA vaccine will include 30 melanoma patients at the Herzen Cancer Research Institute and another 30 patients at the Blokhin National Cancer Medical Research Center.

On September 23, Alexander Gintsburg, Director of the Russian National Research Center for Epidemiology and Microbiology (Gamaleya), stated that Russian experts are ready to use mRNA vaccines for cancer patients in about a month.

According to a VNA correspondent in Moscow, Gintsburg said that the application for approval to produce a personalized mRNA vaccine for cancer patients has been submitted to the Russian Ministry of Health and is awaiting approval.

In addition, groups of volunteers participating in this vaccine trial program have been formed and their genetic data has been finalized.

In an earlier announcement, Gintsburg said the first people to receive the personalized mRNA vaccine would include 30 melanoma patients at the Herzen Cancer Research Institute and another 30 patients at the Blokhin National Cancer Medical Research Center.

Gintsburg expressed hope that the Gamaleya center and the Herzen and Blokhin institutes would soon be licensed to produce the first personalized melanoma vaccines.

According to Veronika Skvortsova, head of the Federal Agency for Medical and Biological Sciences of Russia (FMBA), studies have demonstrated the safety of personalized mRNA vaccines in helping to reduce the size and significantly slow the growth of tumors (potentially by up to 60-80%).

In addition, studies have also shown an increase in survival rates for patients.

(VNA/Vietnam+)

Source: https://www.vietnamplus.vn/nga-se-som-dung-thu-vaccine-mrna-cho-cac-benh-nhan-ung-thu-post1063568.vnp